|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005954,
umls-concept:C0017262,
umls-concept:C0021044,
umls-concept:C0023434,
umls-concept:C0030705,
umls-concept:C0185117,
umls-concept:C0442726,
umls-concept:C0442821,
umls-concept:C1421567,
umls-concept:C1511790,
umls-concept:C1514474,
umls-concept:C1527940,
umls-concept:C1705831,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-14
|
|
pubmed:abstractText |
Zeta-associated protein-70 (ZAP-70), mostly assessed by flow-cytometry (FC), recently emerged as reliable prognostic factor in chronic lymphocytic leukaemia (CLL) at presentation. We evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry (IHC) on formalin-fixed bone marrow (BM) biopsies at diagnosis. At presentation, 117 patients (75%) were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). ZAP-70 was expressed in neoplastic lymphocytes of 69 patients (44%). Concordance between ZAP-70 by IHC and ZAP-70 by FC, immunoglobulin heavy chain variable genes (IGHV) mutational status and CD38 expression was found in 41/46 (89%), 41/49 (80%) and in 60/88 (68%) tested cases, respectively. ZAP-70 expression significantly correlated with advanced Binet stage (B-C), diffuse BM infiltration, increased lactate dehydrogenase (LDH) and beta2-microglobulin serum levels and lymphocyte doubling time <12 months. ZAP-70 positivity was significantly related to poorer time to progression (median 16 months vs 158 of ZAP-70-negative cases) (P<0.0001) and overall survival (median 106 months vs not reached) (P=0.0002); this correlation was confirmed at multivariate analysis. ZAP-70 expression correlated with poorer outcome also when evaluated only in the 117 stage A patients. In conclusion, immunohistological detection of ZAP-70 on formalin-fixed BM biopsies at diagnosis appears a useful methodological approach to identify patients with poor prognosis in CLL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
pubmed-author:AmbrosettiAA,
pubmed-author:Caligaris-CappioFF,
pubmed-author:ChilosiMM,
pubmed-author:GhiaPP,
pubmed-author:GuidaGG,
pubmed-author:LestaniMM,
pubmed-author:MenestrinaFF,
pubmed-author:PattaroCC,
pubmed-author:PerbelliniOO,
pubmed-author:PizzoloGG,
pubmed-author:PratsCC,
pubmed-author:StellaSS,
pubmed-author:UTEIN INI,
pubmed-author:ZanettiFF,
pubmed-author:ZanottiRR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
102-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17082778-Adult,
pubmed-meshheading:17082778-Aged,
pubmed-meshheading:17082778-Antigens, CD38,
pubmed-meshheading:17082778-Biopsy,
pubmed-meshheading:17082778-Bone Marrow,
pubmed-meshheading:17082778-Disease Progression,
pubmed-meshheading:17082778-Female,
pubmed-meshheading:17082778-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17082778-Genes, Immunoglobulin,
pubmed-meshheading:17082778-Humans,
pubmed-meshheading:17082778-Immunoglobulin Heavy Chains,
pubmed-meshheading:17082778-Immunoglobulin Variable Region,
pubmed-meshheading:17082778-Immunohistochemistry,
pubmed-meshheading:17082778-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:17082778-Male,
pubmed-meshheading:17082778-Middle Aged,
pubmed-meshheading:17082778-Predictive Value of Tests,
pubmed-meshheading:17082778-Prognosis,
pubmed-meshheading:17082778-Retrospective Studies,
pubmed-meshheading:17082778-Survival Analysis,
pubmed-meshheading:17082778-Tumor Markers, Biological,
pubmed-meshheading:17082778-Up-Regulation,
pubmed-meshheading:17082778-ZAP-70 Protein-Tyrosine Kinase
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
|
|
pubmed:affiliation |
Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
